Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Periodic Table and Organismal Elements00:57

The Periodic Table and Organismal Elements

OverviewElements are the smallest units of matter that cannot be broken down further by chemical processes. There are 118 known elements, but not all of these are naturally-occurring, and fewer still are essential for life. Living matter is composed primarily of carbon, nitrogen, hydrogen, and oxygen, with smaller amounts of other elements like calcium, phosphorus, potassium, and sulfur. Other elements are also necessary for life but only in trace amounts.The Periodic Table Provides Information...
The Early Endosome: Endocytosis of Transferrin01:28

The Early Endosome: Endocytosis of Transferrin

Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Microbes and Other Elemental Cycles01:24

Microbes and Other Elemental Cycles

Microbial activity plays a pivotal role in the biogeochemical cycling of iron and manganese, especially at the redox gradients characteristic of stratified aquatic environments. These cycles are driven by microbial transformations between oxidized and reduced forms of the metals, allowing organisms to exploit them for metabolic energy and structural purposes.Iron Cycling Across Redox GradientsIn neutral, oxygen-rich surface waters, iron is predominantly found in its oxidized, insoluble ferric...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies.

HemaSphere·2026
Same author

A new 308 A-G substitution in HBG2 in an acyanotic newborn: case report.

Italian journal of pediatrics·2026
Same author

Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrum.

Blood advances·2026
Same author

Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red blood cell and iron disorders.

Blood·2026
Same author

Revisiting LSDMCA: male lethality escape and genotype-phenotype correlations.

European journal of human genetics : EJHG·2026
Same author

A Complex Neurodevelopmental Phenotype Resembling a Chromatinopathy With Concurrent 7p Duplication and 10p Deletion Involving ZMYND11: A Case Report and Literature Review.

Molecular genetics & genomic medicine·2026

Related Experiment Video

Updated: May 10, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Iron refractory iron deficiency anemia.

Luigia De Falco1, Mayka Sanchez, Laura Silvestri

  • 1Ceinge, Biotecnologie Avanzate, Naples, Italy.

Haematologica
|June 5, 2013
PubMed
Summary

Iron refractory iron deficiency anemia, caused by TMPRSS6 gene defects, leads to high hepcidin and poor response to iron. Understanding Matriptase-2

More Related Videos

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

A Colorimetric Method for Measuring Iron Content in Plants
07:12

A Colorimetric Method for Measuring Iron Content in Plants

Published on: September 7, 2018

Related Experiment Videos

Last Updated: May 10, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

A Colorimetric Method for Measuring Iron Content in Plants
07:12

A Colorimetric Method for Measuring Iron Content in Plants

Published on: September 7, 2018

Area of Science:

  • Genetics and Hematology
  • Molecular Medicine
  • Iron Metabolism

Background:

  • Iron refractory iron deficiency anemia (IRIDA) is a rare genetic disorder.
  • It stems from defects in the TMPRSS6 gene, which encodes Matriptase-2.
  • Matriptase-2 is crucial for regulating hepcidin, the main controller of iron homeostasis.

Purpose of the Study:

  • To elucidate the role of Matriptase-2 in iron metabolism and IRIDA.
  • To understand the mechanism linking TMPRSS6 mutations to hepcidin dysregulation.
  • To highlight diagnostic and therapeutic challenges in IRIDA.

Main Methods:

  • Analysis of TMPRSS6 gene mutations in patients with IRIDA.
  • In vitro studies using transfected cells to assess Matriptase-2 function.
  • Correlation of genetic findings with clinical presentation, iron status, and hepcidin levels.

Main Results:

  • Forty TMPRSS6 mutations identified, affecting Matriptase-2's functional domains.
  • Evidence suggests Matriptase-2 cleaves Hemojuvelin, regulating hepcidin expression.
  • Patients exhibit microcytic anemia, low transferrin saturation, and inappropriately high hepcidin.
  • This leads to refractoriness to oral iron and a limited response to intravenous iron.

Conclusions:

  • TMPRSS6 mutations impair Matriptase-2's ability to down-regulate hepcidin.
  • Inappropriately elevated hepcidin in IRIDA causes iron deficiency anemia.
  • Accurate diagnosis is vital to differentiate IRIDA from common iron deficiency anemias.
  • Parenteral iron is the current treatment; future therapies may target the hepcidin pathway.